Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. , the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. , the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
This drug is being developed by Regeneron Pharmaceuticals.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).